Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong
A legfontosabb adatok
- Ki végzi
- The University of Hong Kong
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 4. fázis
- Résztvevők
- 1861 fő vett részt
- Kezdés
- 2017. okt. 7.
- Befejezés
- 2025. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 11 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Standard inactivated influenza vaccine (NH formulation)
- MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- High-dose inactivated influenza vaccine (NH formulation)
- Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
- A regiszteradat frissítve
- 2026. május 15.
Ki vehet részt
- Életkor
- 65 év – 82 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 5 feltétel megnézéseKevesebb
Ki vehet részt
- Adult aged 65-82 years attending ECC and EDC who has not received 2017/18 seasonal influenza vaccine and is willing to receive annual influenza vaccination
Ki nem vehet részt
- Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:; Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component, including egg protein; Moderate or severe acute illness with or without fever after any previous influenza vaccination; or; A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination
- Individuals who show signs of dementia (do not pass the Mini-cog test under Appendix 1a: Recruitment Screening Log) or significant cognitive impairment and are not competent to give their consent
- Individuals, who report medical conditions not suitable to receive intramuscular injection, such as:; bleeding disorders; habitually taking anticoagulants (with the exception of antiplatelets such as aspirin)
- Individuals who have any medical conditions not suitable to receive inactivated influenza vaccines as determined by a clinician
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.
A vizsgálat 11 csoportja
- Standard vaccineMár használt kezelés, összehasonlításként
Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: Standard inactivated influenza vaccine (NH formulation)
- Alternating standard vaccine & adjuvanted vaccineA vizsgált kezelés
Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: Standard inactivated influenza vaccine (NH formulation) és MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- Alternating adjuvanted vaccine & standard vaccineA vizsgált kezelés
Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: Standard inactivated influenza vaccine (NH formulation) és MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- Alternating standard vaccine and high-dose vaccineA vizsgált kezelés
Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: Standard inactivated influenza vaccine (NH formulation) és High-dose inactivated influenza vaccine (NH formulation)
- Alternating high-dose vaccine and standard vaccineA vizsgált kezelés
Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: Standard inactivated influenza vaccine (NH formulation) és High-dose inactivated influenza vaccine (NH formulation)
- Alternating adjuvanted vaccine and high-dose vaccineA vizsgált kezelés
Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) és High-dose inactivated influenza vaccine (NH formulation)
- Alternating high-dose vaccine and adjuvanted vaccineA vizsgált kezelés
Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) és High-dose inactivated influenza vaccine (NH formulation)
- High-dose vaccineA vizsgált kezelés
Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: High-dose inactivated influenza vaccine (NH formulation)
- Adjuvanted vaccineA vizsgált kezelés
Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- Recombinant vaccineA vizsgált kezelés
Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
- Alternating recombinant vaccine and adjuvanted vaccineA vizsgált kezelés
Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Kezelés: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) és Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial
- Publikációk
- Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial.The Journal of infectious diseases, 2026
- Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025
- Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020
- Comparative Reactogenicity of Enhanced Influenza Vaccines in Older Adults.The Journal of infectious diseases, 2020
- A regiszteradat frissítve
- 2026. május 15.